-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
![BSH Thumbnail 1](https://volition.com/wp-content/uploads/2024/04/BSH-Thumbnail-1.png)
Physical isolation of tumour associated ctDNA fragments for novel AML liquid biopsy
- Share
- Tweet
- Share on Facebook
- Share
![BSH Thumbnail 2](https://volition.com/wp-content/uploads/2024/04/BSH-Thumbnail-2.png)
![BSH Thumbnail 2](https://volition.com/wp-content/uploads/2024/04/BSH-Thumbnail-2.png)
Poster title: Physical isolation of tumour associated ctDNA fragments for novel AML liquid biopsy
Presented at BSH 2024
Pamart et al
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields